Collegium Pharmaceutical Prepares for Q2 2025 Financial Results
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is gearing up to share its financial outcomes for the second quarter of 2025. The presentation will occur before the market opens on an anticipated Thursday. Moreover, interested stakeholders can tune in to a live conference call and webcast set to commence at 8:00 a.m. Eastern Time on the same day.
Details of the Conference Call
For those looking to delve deeper into the company's performance, accessing the conference call is straightforward. Participants have the option to dial a dedicated number, with separate lines for U.S. and international attendees. This dialog allows investors and analysts to gain insights into the results and the strategic direction of Collegium following the report.
How to Join the Conference Call
To participate, attendees in the U.S. can call (877) 407-8037, while international participants may connect at (201) 689-8037. When calling, listeners should mention the "Collegium Pharmaceutical Q2 2025 Earnings Call" to ensure they are in the right session. For a broader audience, an audio webcast will be available in the Investors section of the company's official website, providing access to relayed information shortly after the event.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. has established a strong reputation as a leader in the biopharmaceutical sector, particularly in areas affecting individuals with serious medical conditions. The company focuses on creating and marketing responsible pain management medications. A notable addition to their portfolio is Jornay PM, a treatment for ADHD which signifies their expansion into neuropsychiatry.
Strategic Growth Initiatives
The strategic roadmap for Collegium involves a concerted effort to expand its commercial offerings. Jornay PM serves as a primary growth driver while the company aims to wisely invest its capital in various prospective ventures. With a commitment to enhancing the quality of life for patients, Collegium continuously seeks innovative solutions to meet their needs.
Staying Informed with Collegium
For individuals keen on understanding Collegium's trajectory and future activities, the company's website remains a resourceful hub. Investors and interested parties can find robust updates from financial reports to company news. Collegium encourages all stakeholders to stay engaged through regular visits to its digital platforms.
Contact Information
The investor relations team at Collegium is always ready to assist. For inquiries regarding investor relations, interested individuals can reach out via email to Ian Karp, the Head of Investor Relations, or Danielle Jesse, the Director of Investor Relations. Their commitment to transparency ensures that stakeholders have the information they require.
Frequently Asked Questions
What financial results are being reported by Collegium?
Collegium will report its financial outcomes for the second quarter of 2025.
When will the conference call take place?
The conference call is scheduled for 8:00 a.m. ET on the day the financial results are announced.
How can I participate in the conference call?
You can call (877) 407-8037 for U.S. listeners or (201) 689-8037 for international callers.
What is Jornay PM?
Jornay PM is Collegium's ADHD treatment that recently expanded its portfolio.
Who can I contact for investor relations inquiries?
You can email Ian Karp or Danielle Jesse for inquiries related to investor relations at Collegium.
